SPR 720

Drug Profile

SPR 720

Alternative Names: SPR-720

Latest Information Update: 12 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Spero Therapeutics
  • Class
  • Mechanism of Action DNA gyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mycobacterial infections; Tuberculosis

Most Recent Events

  • 04 May 2017 Spero Therapeutics receives SBIR grant from NIH for SPR 720 development in Tuberculosis
  • 04 May 2017 Preclinical trials in Tuberculosis in USA (PO)
  • 02 May 2017 Spero Therapeutics announces intention to submit IND application for Mycobacterial infections in first quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top